Zacks Investment Research on MSN

Here's why DexCom (DXCM) is a strong growth stock

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...
Bell Global Equities Fund, managed by Bell Asset Management, released its May investor update. A copy of the letter can be ...
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
DexCom (DXCM) stock has been in focus after Investor Day communications that many fund managers say improved sentiment, ...
DexCom develops and markets continuous glucose monitoring (CGM) systems, a type of device that continuously tracks blood sugar levels. The technology isn't exactly new anymore, and it has enjoyed ...
The FDA’s indication expansion for Dexcom’s Stelo makes it the first over the counter CGM available for children, including those with diabetes.
Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...
DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...
In a report released on July 6, Joanne Wuensch from Citi reiterated a Buy rating on Dexcom, with a price target of $84.00. The company’s shares closed yesterday at $72.38. 55% O ...
Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...
Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...